border=0
border=0
Enter any ticker symbol here to see the live quote & chart tools in action
Ticker:   
border=0 border=0 Benefits: /
  • Your filings are automatically published to your site as they are filed.
  • Investors don't have to leave your site to see filings.


  • Product Description
  • Once a report has been filed with the SEC it will be available on the website.



  • SEC Filings Section 16 Filings Only
     
    NOVADEL PHARMA INC filed this 8-K on 06/12/2007.
               Outline Printer Friendly Entire FilingNext Page »
    c48994_8k.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM 8-K

    CURRENT REPORT PURSUANT
    TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported) June 6, 2007

     

    NOVADEL PHARMA INC.
    (Exact Name of Registrant as Specified in Its Charter)

    Delaware  001-32177  22-2407152 
    (State or other jurisdiction  (Commission File No.)  (I.R.S. Employer 
    of incorporation or organization)    Identification No.) 

         25 Minneakoning Road
    Flemington, New Jersey 08822
    (Address of principal executive offices) (Zip Code)

    (908) 782-3431
    (Registrant’s telephone number, including area code)

    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


    Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

    Effective June 6, 2007, the Board of Directors (the “Board”) of NovaDel Pharma Inc., a Delaware corporation (the “Company”) and Mr. Steven B. Ratoff, Chairman of the Board, agreed to revise the current consulting arrangement with Mr. Ratoff to reflect an increase in his day-to-day involvement with the Company. The Company had previously been compensating Mr. Ratoff at a rate of $10,000 per month and reimbursement of reasonable expenses for his services to the Company. Under the new consulting arrangement, Mr. Ratoff will increase his services to the Company and, as a result, the Company will compensate Mr. Ratoff at a rate of $17,500 per month and reimbursement of reasonable expenses. The consulting arrangement with Mr. Ratoff is on a month-to-month basis.

     






    border=0
    Quote & Chart Package
    Basic Stock Chart
    Basic Stock Quote
    Embedded Quote / Chart
    Embedded Full Quote / Chart
    Interactive Chart
    Intraday Chart
    Pop Up Quote
    Scrolling Ticker

    You are viewing our Quote and Chart Demo using ticker symbol NVDL
    border=0

    T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer